This company has been marked as potentially delisted and may not be actively trading. Gemphire Therapeutics (GEMP) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock GEMP vs. ELYM, HILS, EGRX, MRNS, ALLK, CARA, NNVC, ME, IBIO, and GLYCShould you be buying Gemphire Therapeutics stock or one of its competitors? The main competitors of Gemphire Therapeutics include Eliem Therapeutics (ELYM), Hillstream BioPharma (HILS), Eagle Pharmaceuticals (EGRX), Marinus Pharmaceuticals (MRNS), Allakos (ALLK), Cara Therapeutics (CARA), NanoViricides (NNVC), 23andMe (ME), iBio (IBIO), and GlycoMimetics (GLYC). These companies are all part of the "medical" sector. Gemphire Therapeutics vs. Its Competitors Eliem Therapeutics Hillstream BioPharma Eagle Pharmaceuticals Marinus Pharmaceuticals Allakos Cara Therapeutics NanoViricides 23andMe iBio GlycoMimetics Eliem Therapeutics (NASDAQ:ELYM) and Gemphire Therapeutics (NASDAQ:GEMP) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, risk, analyst recommendations, profitability, media sentiment, dividends, earnings and valuation. Which has more volatility and risk, ELYM or GEMP? Eliem Therapeutics has a beta of -0.39, indicating that its stock price is 139% less volatile than the S&P 500. Comparatively, Gemphire Therapeutics has a beta of 2.82, indicating that its stock price is 182% more volatile than the S&P 500. Does the media favor ELYM or GEMP? In the previous week, Eliem Therapeutics' average media sentiment score of 0.00 equaled Gemphire Therapeutics'average media sentiment score. Company Overall Sentiment Eliem Therapeutics Neutral Gemphire Therapeutics Neutral Do insiders and institutionals believe in ELYM or GEMP? 69.8% of Eliem Therapeutics shares are held by institutional investors. Comparatively, 17.5% of Gemphire Therapeutics shares are held by institutional investors. 4.7% of Eliem Therapeutics shares are held by insiders. Comparatively, 22.7% of Gemphire Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Which has preferable earnings & valuation, ELYM or GEMP? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEliem TherapeuticsN/AN/A-$35.12M-$0.53-2.42Gemphire TherapeuticsN/AN/A-$23.64MN/AN/A Is ELYM or GEMP more profitable? Eliem Therapeutics' return on equity of -47.03% beat Gemphire Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Eliem TherapeuticsN/A -47.03% -45.97% Gemphire Therapeutics N/A -419.70%-173.05% SummaryEliem Therapeutics and Gemphire Therapeutics tied by winning 3 of the 6 factors compared between the two stocks. Get Gemphire Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for GEMP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding GEMP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GEMP vs. The Competition Export to ExcelMetricGemphire TherapeuticsPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$9.25M$784.82M$5.52B$9.02BDividend YieldN/A4.84%5.24%4.07%P/E RatioN/A1.3027.2220.04Price / SalesN/A230.49380.3292.37Price / CashN/A23.4426.2128.59Price / Book1.156.237.945.55Net Income-$23.64M-$27.94M$3.17B$248.49M Gemphire Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GEMPGemphire TherapeuticsN/A$0.62-4.0%N/A-85.7%$9.25MN/A0.009ELYMEliem TherapeuticsN/A$1.24+5.1%N/A-80.7%$36.89MN/A-2.349HILSHillstream BioPharmaN/A$1.80+2.4%N/A-45.3%$31.73MN/A-2.501Gap UpEGRXEagle PharmaceuticalsN/A$2.36-18.6%N/A-45.5%$30.65M$257.55M0.00100Gap DownMRNSMarinus Pharmaceuticals2.3172 of 5 stars$0.55-0.2%$3.92+613.3%-54.2%$30.32M$30.99M-0.22110ALLKAllakos2.8571 of 5 stars$0.33flat$2.00+507.7%N/A$29.74MN/A-0.16190CARACara Therapeutics0.34 of 5 starsN/AN/AN/A$24.33M$7.14M-0.2580Gap DownHigh Trading VolumeNNVCNanoViricides0.9481 of 5 stars$1.40flatN/A-21.1%$22.50MN/A-1.9420News CoverageGap DownME23andMeN/A$0.50-35.3%N/A-94.2%$13.36M$208.78M-0.03770Gap DownHigh Trading VolumeIBIOiBio1.8849 of 5 stars$0.75-1.7%$4.30+473.4%-59.1%$12.39M$375K0.00100GLYCGlycoMimetics1.1471 of 5 stars$0.16-6.6%N/A-99.4%$10.00M$10K-0.3450High Trading Volume Related Companies and Tools Related Companies Eliem Therapeutics Competitors Hillstream BioPharma Competitors Eagle Pharmaceuticals Competitors Marinus Pharmaceuticals Competitors Allakos Competitors Cara Therapeutics Competitors NanoViricides Competitors 23andMe Competitors iBio Competitors GlycoMimetics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GEMP) was last updated on 7/8/2025 by MarketBeat.com Staff From Our PartnersEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredF1 Engineering Powers This Electric Marine MotorThe future of marine propulsion has arrived - powered by F-1 grade engineering. In collaboration with McLar...The Tomorrow Investor | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredInstant Cash (in 4 clicks)Since 1973, Wall Street has quietly used a strange little pricing quirk to cash flow billions. Now, for the...Awesomely, LLC | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredForget Nvidia, This “Ghost Town” Company Holds the Key to the AI BoomCold War Discovery Could Unlock $100 Trillion in Wealth Jeff recently traveled to an American ghost town to...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Gemphire Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Gemphire Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
